Anticancer agent 53
Anticancer agent 53 is a potent anticancer agent. Anticancer agent 53 shows in vitro cytotoxicity. Anticancer agent 53 induces apoptosis and cell cycle arrest in S/G2/M phases. Anticancer agent 53 shows antitumor activity with no apparent toxicity.
For research use only. We do not sell to patients.
- CAS No.: 1926985-18-3
- Formula: C31H25FN4O6S
- Molecular Weight:600.62
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
4.3 nM
Compound: c20
|
Cytotoxicity against human A549 cells assessed as growth inhibition measured after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as growth inhibition measured after 72 hrs by MTT assay
|
[PMID: 31881457] |
| Hep 3B2 | IC50 |
2.3 nM
Compound: c20
|
Cytotoxicity against human Hep3B cells assessed as growth inhibition measured after 72 hrs by MTT assay
Cytotoxicity against human Hep3B cells assessed as growth inhibition measured after 72 hrs by MTT assay
|
[PMID: 31881457] |
| KB | IC50 |
24 nM
Compound: c20
|
Cytotoxicity against human KB cells assessed as growth inhibition measured after 72 hrs by MTT assay
Cytotoxicity against human KB cells assessed as growth inhibition measured after 72 hrs by MTT assay
|
[PMID: 31881457] |
| MCF7 | IC50 |
42 nM
Compound: c20
|
Cytotoxicity against human MCF7 cells assessed as growth inhibition measured after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as growth inhibition measured after 72 hrs by MTT assay
|
[PMID: 31881457] |
| MDA-MB-231 | IC50 |
96.3 nM
Compound: c20
|
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition measured after 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition measured after 72 hrs by MTT assay
|
[PMID: 31881457] |
In Vitro
Anticancer agent 53 (compound c20) (0-1000 nM; 72 h) shows cytotoxicity with IC50s of 2.3, 42.0, 4.3, 96.3, 24.0, 47.4 nM for Hep3B, MCF7, A549, MDA-MB-231, KB, KB-vin cells, respectively[1].
Anticancer agent 53 (0.025, 0.05, 0.1 µM; 48 h) induces apoptosis and cell cycle arrest in S/G2/M phases[1].
Anticancer agent 53 (0.1. 0.2 µM; 6 h) inhibits topoisomerase I activity in A549 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:A549 cells
-
Concentration:0.025, 0.05, 0.1 µM
-
Incubation Time:0-48 h
-
Result:Induced cell cycle arrest in S/G2/M phases.
-
Cell Line:A549 cells
-
Concentration:0.025, 0.05, 0.1 µM
-
Incubation Time:0-48 h
-
Result:Induced apoptosis with the proapoptotic protein Caspase-3 and Bax were up-regulated and anti-apoptotic Bcl-2 was down-regulated.
In Vivo
Anticancer agent 53 (2 mg/kg; i.v; every other day for two weeks) shows antitumor effect in HCC mouse model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/C mice[1]
-
Dosage:5, 25 and 50 mg/kg (saline with 5% DMSO and 5% Cremophor EL)
-
Administration:I.p.
-
Result:Showed no body weight loss, no significant liver damage, no significant damage occurred in spleens and livers.
-
Animal Model:6-8 weeks Female BALB/c nude mice (Hep3B cells)[1]
-
Dosage:1, 2 mg/kg
-
Administration:I.v., every other day for total 7 doses
-
Result:Significantly inhibited tumor growth with an average body weight of 24 g and an average tumor volume of 3800 mm[3] at 1 mg/kg and an average body weight of 22 g and average tumor volume 2380 mm[3] at 2 mg/kg.
-
Animal Model:6-8 weeks FVB/N mice (HCC mouse model)[1]
-
Dosage:2 mg/kg
-
Administration:I.v.; every other day for two weeks
-
Result:Inhibited the tumor growth and reduced the liver weights, and t inhibited proliferation of HCC tissues.
Chemical Information
-
CAS No. 1926985-18-3
-
Molecular Weight 600.62
-
Formula C31H25FN4O6S
-
SMILES
CC[C@]1(C(OCC2=C1C=C3C4=NC5=CC=CC=C5C=C4CN3C2=O)=O)OC([C@@H](NC(NC(C6=CC=C(C=C6)F)=O)=S)C)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)